PowerUp shareholders approve merger with Aspire Biopharma; redemptions of ~$5.8M

Aspire Biopharma Holdings, Inc.

All proposals approved at Feb 4 meeting, including business combination, domestication, and charter changes.
507,631 shares redeemed for $5.8M ($11.43/share), leaving ~$5.8M removed from trust.
Closing expected before Feb 17, 2025; combined company to trade as ASBP (common) and ASBPW (warrants) on Nasdaq.
Seven directors elected to staggered board, including Kraig Higginson, Michael Howe, Gary Stein, others.
Adjournment proposal not needed due to sufficient votes for all proposals.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.